FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979484252> ?p ?o ?g. }

• W2979484252 abstract "Abstract Abstract 3019 Background: Radioimmunotherapy (RIT) is an effective and manageable treatment option for those patients (pts) affected by follicular B-cell lymphoma (FL) who experience disease relapse. The results of RIT in the setting of first line consolidation are also very promising in terms of progression free and overall survival. On the other hand autologous stem cell transplantation (ASCT) is a suitable treatment option for relapsed FL patients. Although major concerns about the widespread use of RIT early in the disease course are the long term hematologic toxicity and the theoretical possible irreparable damage to bone marrow function with impairment of peripheral stem cell harvest, very few data are available about mobilization rates after Zevalin exposure. Methods: The aim of this monocentric study was to analyze the impact of prior Zevalin administration on peripheral blood stem cells (PBSC) mobilization and on the outcome of subsequent ASCT. Moreover the impact of different prior treatment regimens [Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (R-CHOP) or CHOP-like regimens vs Fludarabine, Mitoxantrone plus Rituximab (FM-R) vs Zevalin] and number of previous lines of therapy given earlier in the disease course, was prospectively evaluated in all FL patients (n=100) who underwent stem cell mobilization from January 2005 to March 2012. Results: At the time of mobilization, 68 pts had received R-CHOP or CHOP-like regimens, 20 pts FM-R, 12 pts RIT with Zevalin earlier in the disease course. Characteristics of pts such as age, weight and number of prior therapies, were well balanced in the 3 groups. Sixty one pts had received one prior therapy, 31 pts 2 therapies, 8 pts ≥ 3 lines of therapy. All pts received chemotherapy plus granulocyte colony stimulating factor (G-CSF) 5 μg/kg (n=94) or G-CSF alone (10 μg/kg) (n=6) as mobilization regimen. Mean CD34+ cells yield was 8.9 × 106/kg in the CHOP group, vs 5.8 × 106 CD34 + cells/kg in the FM-R group, vs 2.7 × 106 CD34 + cells/kg in the Zevalin group (p=0.05 CHOP vs FM-R; p<0.001 CHOP vs Zevalin; p<0.01 FM-R vs Zevalin; t test). The collection yield of 2.0 × 106 CD34 + cells/kg was reached in 98% (n=67) of pts in the CHOP group, vs 80% (n=16) in the FM-R group, vs 42% (n=5) in the Zevalin group. The number of previous treatments did not significantly affect PBSC harvest (1 vs 2 lines: p=0.1; 1 vs 3 lines: p=0.1; 2 vs 3 lines: p=0.3). Regarding the engraftment no differences were noted between the 3 groups and the median time to neutrophils (> 1000/μL) and platelets recovery (>20000/μL) was 10 and 11 days in all groups respectively. Only one pt in the CHOP group and one in the FM-R group did not undergo ASCT because of insufficient CD34+ harvest. Considering the Zevalin group (n=12), median age was 51 years (range 36–66). Seven pts received Zevalin as first line consolidation, 5 patients at disease relapse. Median number of prior therapies was 2 (range 1–4). Ten pts received chemotherapy plus G-CSF as initial mobilization regimen, 2 pts received G-CSF alone. Median time from RIT to mobilization was 13 months (4–60 months). Five pts (42%) reached the collection yield of > 2.0 × 106 CD34 + cells/kg with the first mobilization attempt. Considering the remaining 7 pts who failed (CD34+ cells below 10/mL before apheresis, or cell harvest below 2.0 × 106 CD34 + cells/kg), a surgical procedure was attempted in 4 pts, G-CSF + Plerixafor (240 μg/kg) in 3 pts. Remarkably the second harvest allowed 5 additional pts (3 pts after surgery, 2 pts after G-CSF + Plerixafor) to undergo ASCT. Finally ASCT was succesfully performed in 9 pts (75%). Median number of reinfused CD34+ cells was 2.3 × 106 CD34 + cells/kg (0.4–4.2). Three pts did not undergo ASCT, one because of disease progression, 2 pts because of insufficient CD34+ harvest. Conclusions: The type of previous therapy may significantly influence the mobilization rate in FL pts. Although mobilization was significantly impaired in pts previously treated with Zevalin compared to other chemotherapy regimens, stem cell harvest after RIT was feasible and the vast majority of patients retained the possibility to undergo ASCT with a second stem cell harvest, with no significant impact on engraftment. The use of Plerixafor seems to be particularly promising for those patients previously exposed to RIT who failed the first mobilization. Disclosures: No relevant conflicts of interest to declare." @default.
• W2979484252 created "2019-10-18" @default.
• W2979484252 creator A5002306207 @default.
• W2979484252 creator A5003017329 @default.
• W2979484252 creator A5013366738 @default.
• W2979484252 creator A5037030903 @default.
• W2979484252 creator A5039739851 @default.
• W2979484252 creator A5044224344 @default.
• W2979484252 creator A5044832096 @default.
• W2979484252 creator A5046793649 @default.
• W2979484252 creator A5060396380 @default.
• W2979484252 creator A5070351821 @default.
• W2979484252 creator A5079336756 @default.
• W2979484252 creator A5090561717 @default.
• W2979484252 date "2012-11-16" @default.
• W2979484252 modified "2023-09-27" @default.
• W2979484252 title "Collection of Hematopoietic Stem Cells After Previous Exposure to Ittrium-90 Ibritumumab Tiuxetan (Zevalin) Is Feasible and Does Not Impair Autologous Stem Cell Transplantation Outcome in Follicular Lymphoma." @default.
• W2979484252 doi "https://doi.org/10.1182/blood.v120.21.3019.3019" @default.
• W2979484252 hasPublicationYear "2012" @default.
• W2979484252 type Work @default.
• W2979484252 sameAs 2979484252 @default.
• W2979484252 citedByCount "0" @default.
• W2979484252 crossrefType "journal-article" @default.
• W2979484252 hasAuthorship W2979484252A5002306207 @default.
• W2979484252 hasAuthorship W2979484252A5003017329 @default.
• W2979484252 hasAuthorship W2979484252A5013366738 @default.
• W2979484252 hasAuthorship W2979484252A5037030903 @default.
• W2979484252 hasAuthorship W2979484252A5039739851 @default.
• W2979484252 hasAuthorship W2979484252A5044224344 @default.
• W2979484252 hasAuthorship W2979484252A5044832096 @default.
• W2979484252 hasAuthorship W2979484252A5046793649 @default.
• W2979484252 hasAuthorship W2979484252A5060396380 @default.
• W2979484252 hasAuthorship W2979484252A5070351821 @default.
• W2979484252 hasAuthorship W2979484252A5079336756 @default.
• W2979484252 hasAuthorship W2979484252A5090561717 @default.
• W2979484252 hasConcept C126322002 @default.
• W2979484252 hasConcept C129470790 @default.
• W2979484252 hasConcept C13373296 @default.
• W2979484252 hasConcept C141071460 @default.
• W2979484252 hasConcept C143998085 @default.
• W2979484252 hasConcept C159654299 @default.
• W2979484252 hasConcept C170493617 @default.
• W2979484252 hasConcept C203014093 @default.
• W2979484252 hasConcept C2776146153 @default.
• W2979484252 hasConcept C2776694085 @default.
• W2979484252 hasConcept C2776755627 @default.
• W2979484252 hasConcept C2777058707 @default.
• W2979484252 hasConcept C2777408962 @default.
• W2979484252 hasConcept C2778515704 @default.
• W2979484252 hasConcept C2778828106 @default.
• W2979484252 hasConcept C2779050716 @default.
• W2979484252 hasConcept C2779263901 @default.
• W2979484252 hasConcept C2779338263 @default.
• W2979484252 hasConcept C2779429289 @default.
• W2979484252 hasConcept C2779725641 @default.
• W2979484252 hasConcept C2780653079 @default.
• W2979484252 hasConcept C2780923524 @default.
• W2979484252 hasConcept C28328180 @default.
• W2979484252 hasConcept C2911091166 @default.
• W2979484252 hasConcept C542903549 @default.
• W2979484252 hasConcept C54355233 @default.
• W2979484252 hasConcept C71924100 @default.
• W2979484252 hasConcept C86803240 @default.
• W2979484252 hasConcept C90924648 @default.
• W2979484252 hasConceptScore W2979484252C126322002 @default.
• W2979484252 hasConceptScore W2979484252C129470790 @default.
• W2979484252 hasConceptScore W2979484252C13373296 @default.
• W2979484252 hasConceptScore W2979484252C141071460 @default.
• W2979484252 hasConceptScore W2979484252C143998085 @default.
• W2979484252 hasConceptScore W2979484252C159654299 @default.
• W2979484252 hasConceptScore W2979484252C170493617 @default.
• W2979484252 hasConceptScore W2979484252C203014093 @default.
• W2979484252 hasConceptScore W2979484252C2776146153 @default.
• W2979484252 hasConceptScore W2979484252C2776694085 @default.
• W2979484252 hasConceptScore W2979484252C2776755627 @default.
• W2979484252 hasConceptScore W2979484252C2777058707 @default.
• W2979484252 hasConceptScore W2979484252C2777408962 @default.
• W2979484252 hasConceptScore W2979484252C2778515704 @default.
• W2979484252 hasConceptScore W2979484252C2778828106 @default.
• W2979484252 hasConceptScore W2979484252C2779050716 @default.
• W2979484252 hasConceptScore W2979484252C2779263901 @default.
• W2979484252 hasConceptScore W2979484252C2779338263 @default.
• W2979484252 hasConceptScore W2979484252C2779429289 @default.
• W2979484252 hasConceptScore W2979484252C2779725641 @default.
• W2979484252 hasConceptScore W2979484252C2780653079 @default.
• W2979484252 hasConceptScore W2979484252C2780923524 @default.
• W2979484252 hasConceptScore W2979484252C28328180 @default.
• W2979484252 hasConceptScore W2979484252C2911091166 @default.
• W2979484252 hasConceptScore W2979484252C542903549 @default.
• W2979484252 hasConceptScore W2979484252C54355233 @default.
• W2979484252 hasConceptScore W2979484252C71924100 @default.
• W2979484252 hasConceptScore W2979484252C86803240 @default.
• W2979484252 hasConceptScore W2979484252C90924648 @default.
• W2979484252 hasLocation W29794842521 @default.
• W2979484252 hasOpenAccess W2979484252 @default.
• W2979484252 hasPrimaryLocation W29794842521 @default.
• W2979484252 hasRelatedWork W2152801965 @default.
• W2979484252 hasRelatedWork W2474447101 @default.
• W2979484252 hasRelatedWork W2549601537 @default.
• W2979484252 hasRelatedWork W2554904935 @default.

• next